Announcement • Jul 01
Spermosens Provides Update on Ongoing Generation 3 Clinical Study of Juno-Checked Spermosens AB provided an update on the ongoing clinical study of JUNO-Checked Generation 3 at the Reproductive Medicine Centre (RMC) in Malmö. Recruitment is progressing ahead of plan, with 43 patients included to date. The Company's ambition remains, as previously communicated, to complete the study during 2026. The Generation 3 clinical study is a central element in the Company's strategy to demonstrate the clinical value of JUNO-Checked and to pursue commercialization through partnerships. The study evaluates JUNO-Checked, which measures the sperm cell's ability to bind to the egg, in couples undergoing IVF treatment. The clinical data forms the basis for these partner discussions, which the Company continues to advance in parallel with the study. Recruitment has progressed faster than expected so far, supported by a strong collaboration with the clinic and a high willingness among patients to participate. Recruitment will pause during the clinic's summer break and resume mid August. In parallel with the study, the Company is adjusting the parameters of how the test is performed to produce the most accurate results. Validating a new diagnostic technology is a demanding process, and as with any clinical study the outcome and timing are not certain. Spermosens will participate in the Annual Meeting of the European Society of Human Reproduction and Embryology (ESHRE) in London on 5-8 July 2026. The Company has been selected to present the results of its first clinical study, completed in 2025 with the second-generation JUNO-Checked sensor, and will meet companies active in the field. Announcement • Jun 18
Spermosens AB (Publ) Approves Board Elections Spermosens AB (publ) at its AGM held on June 18, 2026 approved the election of Aleksander Giwercman and Klaas Rackebrandt as new Board members. Announcement • May 08
Spermosens AB (publ) announced that it expects to receive SEK 4.85 million in funding Spermosens AB (publ) has announced a private placement to issue units at the price of 15% discount to VWAP for the gross proceeds of SEK 4,850,000 on May, 2026. The transaction involves the existing share holder investor participation and CEO Tore Duvold via Duvold Holding ApS for SEK 0.1 million Chairman Ulrik Spork for SEK 0.1 million Mount Nebo Investments LLC for SEK 2.0 million Seven additional shareholders for SEK 2.65 million combined. Each unit will consist of one share and one warrant issued free of charge. The warrants will have a term of three years and entitle the holder to subscribe for one new share at a subscription Exercise price of SEK 0.025 per share. The warrants may be exercised during one week prior to each half-year during the term. The transaction is approved by board of directors and subject to approval of shareholders at the AGM on June 18, 2026 for authorization to issue securities. 
